Group 4 Created with Sketch.

A Novel, First-in-class, Photodynamic Therapy for Patients with CTCL

Share
station description Updates from all Oncology & Hematology Disciplines and Sub-specialties.
The Onco'Zine Brief
Duration: 46:00
In this episode of The Onco’Zine Brief Peter Hofland Ph.D. talks with Ellen J. Kim, MD. Kim is the Medical Director of the Dermatology Clinic at the Perelman Center for Advanced Medicine and Professor of Dermatology at the Hospital of the University of Pennsylvania. She is also the Lead Principal I
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Snippets: Clips of A Novel, First-in-class, Photodynamic Therapy for Patients with CTCL that people like
There are currently no snippets from A Novel, First-in-class, Photodynamic Therapy for Patients with CTCL.
Snippets are an easy way to highlight your favorite soundbite from any piece of audio and share with friends, or make a trailer for The Onco'Zine Brief
Playlists that A Novel, First-in-class, Photodynamic Therapy for Patients with CTCL appears on.
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Add to Playlist
Up Next
Full Description
Back to Top
In this episode of The Onco’Zine Brief Peter Hofland Ph.D. talks with Ellen J. Kim, MD. Kim is the Medical Director of the Dermatology Clinic at the Perelman Center for Advanced Medicine and Professor of Dermatology at the Hospital of the University of Pennsylvania. She is also the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL). This study is the largest multicenter, randomized, double-blind, placebo-controlled, skin-directed therapy study in cutaneous T-cell lymphoma, to date, enrolling a total of 169 patients.In our program today Hofland and Kim talk about the success of HyBryte™ (previously known as (SGX301); hypericin ointment 0.25%) in the broad cutaneous T-cell lymphoma patient population.HyBryte™, being developed by Soligenix, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light 16 to 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other types of phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited the growth of malignant T-cells isolated from CTCL patients. In a published Phase 2 clinical study in CTCL, patients experienced a statistically significant (p=0.04) improvement with topical hypericin treatment whereas the placebo was ineffective. HyBryte™ has received orphan drug and fast track designations from the FDA, as well as an orphan designation from the European Medicines Agency (EMA).About The Onco'Zine BriefThe Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program.For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.comTo sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.ReferenceFLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) - NCT02448381
Up Next
Add to playlist
New playlist

Embed

COPY
Embed Options
Create Playlist
Select the Station you want to upload this audio to
Station
0 / 140
0 / 2000
Playlist Icon Image:
(.jpg, .png, min size 500x500px)
Privacy
Subscribers
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Password reset

Enter your email address that you used to register. We'll send you an email with your username and a link to reset your password.



If you still need help, contact Vurbl Support
Password reset sent

You have been sent instructions on resetting you password to the email associated with your account. Please check your email and signing in again.


Back to Sign In
If you still need help, contact Vurbl Support
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Reset password

Please enter your new password below.



If you still need help, contact Vurbl Support
Your voice matters.
Discover & Listen to the world’s largest free collection of audio
Verify Email

Enter your email address that you used to register. We'll send you an email with a link to verify your email.



Cancel
Delete Profile
Are you sure? We will miss you :'(
Delete
Delete Audio
Are you sure?
Delete
Delete Playlist
Are you sure you want to delete this playlist?
Delete
Notifications
You must be signed in to view
your notifications. Please sign in
Edit Snippet
0 / 140
0 / 140

Tag a Station

Type station name to add additional tags
*Station owners will be notified when you tag them
Open this link in the Vurbl Mobile App for the full Vurbl experience.
Open in Vurbl mobile app
Continue to Vurbl website